TriangleFour week alternating FOLFOX and… (NCT05332002)
Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI) trial for Gastro-Intestinal Cancer (NCT05332002). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable or metastatic HER2-negative stomach, gastroesophageal-junction or esophageal adenocarcinoma. Previous metastatic treatment is restricted, although up to two mFOLFOX6 cycles can qualify.
The idea: alternate four-week blocks of FOLFOX and FOLFIRI chemotherapy. Oxaliplatin damages DNA; irinotecan disrupts DNA copying. Treatment starts on days one and fifteen of each block. Nivolumab is optional under its approved-use rules, not required for everyone. Researchers measure responses, survival and side effects without a comparison group.
This phase 2 study plans 38 patients. Rutgers' Patrick Boland leads six recruiting New Jersey sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.